Title: Medical research lead, Struthers Parkinson’s Center
HealthPartners/Park Nicollet Medical Group title: Associate Consultant, neurology
Academic appointment: Adjunct Professor of Neurology, University of Minnesota, Minneapolis
Education and training: MD, School of Medicine, Aristotle University of Thessaloniki, Thessaloniki, Greece; residency (neurology), University of Minnesota, Minneapolis; PhD (neurophysiology), School of Medicine, Aristotle University of Thessaloniki, Thessaloniki, Greece; Fogarty Fellow, Experimental Therapeutics Branch, National Institute of Neurologic Disorders and Stroke, National Institutes of Health, Bethesda, MD; research fellow, Lab of Neurophysiology, Aristotle’s University of Thessaloniki, Thessaloniki, Greece; advanced clinical fellow (movement disorders), Division of Movement Disorders, Department of Neurology, Mayo Clinic and Mayo Foundation, Rochester, Minnesota.
Overview/research interests: Sotirios A. Parashos, MD, PhD, is medical research lead at the Struthers Parkinson’s Center (Methodist Hospital), a Parkinson’s Foundation Center of Excellence. Dr. Parashos’ research in Parkinson’s disease focuses on non-dopa-responsive symptoms such as falls and cognitive dysfunction, the natural progression of Parkinson’s disease and the role of the multidisciplinary and interdisciplinary care in the management of Parkinson’s disease. He has co-authored many articles published in peer-reviewed journals, a book on Navigating Life with Parkinson’s Disease (part of the American Academy of Neurology’s Neurology Now series) and has given numerous lectures on Parkinson’s disease to professional and lay audiences. Dr. Parashos serves on the Community Advisory Board of the Struthers Parkinson’s Center, on the Work Group for Parkinson’s Disease Physician Performance Measure Development of the Quality Standards Subcommittee of the American Academy of Neurology and on the Quality Improvement Initiative of the Parkinson’s Foundation.
Current research activities and funding:
- Role of attention in gait and balance in Parkinson’s disease; Funder: SPC; Role: Co-PI
- A Phase 3, 12-week, Multicenter, Multinational, Randomized, Double-Blind, Double-Dummy, Parallel Group Study to Determine the Efficacy, Safety and Tolerability of P2B001 Once Daily Compared to its Individual Components in Subjects with Early Parkinson’s Disease and to a Calibration Arm of Pramipexole ER; Funder: Pharma2B; Role; Site PI
- A Phase 3, four-week, Multicenter, Randomized, Double-Blind, Placebo-Controlled, Parallel Group Study of TD-9855 in Treating Symptomatic Neurogenic Orthostatic Hypotension in Subjects with Primary Autonomic Failure; Funder: Theravance Biopharma; Role: Site PI
- A Randomized Controlled Study to Compare the Safety and Efficacy of IPX203 with Immediate-Release Carbidopa-Levodopa in Parkinson’s Disease Patients with Motor Fluctuations; Funder: IMMPAX Laboratories; Role: Site PI
- Evaluation of Oral Anti-Parkinsonian Medication Use in Patients with Advanced Parkinson’s Disease with History of Deep Brain Stimulation (DBS) and Being Treated with Carbidopa Levodopa Enteral Suspension (CLES); Funder: Abbvie; Role: Site PI
- National Parkinson’s Foundation Patient Registry; Funder: NPF; Role: site PI
- Milestones of Disease Progression and Disability in Parkinson’s Disease: A Hypothesis and First Testing; Funder: SPC; Role: site PI
- Risk and Protective Factors for Falls in Parkinson’s Disease; Funder: NPF; Role: Co-investigator